Compulsory generic switching of antiepileptic drugs: High switchback rates to branded compounds compared with other drug classes

Epilepsia

Volumn 48, Issue 3, 2007, Pages 464-469

  Andermann, Frederick ^a,d   Duh, Mei Sheng ^b   Gosselin, Antoine ^c   Paradis, Pierre Emmanuel ^c  

^a MCGILL UNIVERSITY   (Canada)

^b ANALYSIS GROUP   (United States)

^c GROUPE D ANALYSE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Antiepileptic drugs; Epilepsy; Generic substitution; Lamictal; Lamotrigine

Indexed keywords

ANTICONVULSIVE AGENT; ANTILIPEMIC AGENT; CITALOPRAM; CLOBAZAM; FLUOXETINE; LAMOTRIGINE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; VALPROATE SEMISODIUM; VALPROIC ACID;

ARTICLE; CANADA; COMPARATIVE STUDY; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG UTILIZATION; FINANCIAL MANAGEMENT; HUMAN; MONOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; SEIZURE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; EPILEPSY; FEMALE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; KAPLAN-MEIERS ESTIMATE; MALE; ONTARIO; PATIENT ACCEPTANCE OF HEALTH CARE; PRESCRIPTIONS, DRUG; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; TRIAZINES;

EID: 33847629307     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01007.x     Document Type: Article

References (16)

1. American Academy of Neurology. (1990) Assessment: generic substitution for antiepileptic medication. Neurology 40:1641-1643.
2. Besag FM. (2000) Is generic prescribing acceptable in epilepsy? Drug Safety 23:173-182.
3. Borgherini G. (2003) The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clinical Therapeutics 25:1578-1592.
4. Crawford P, Hall WW, Chappell B, Collings J, Stewart A. (1996) Generic prescribing for epilepsy: is it safe? Seizure 5:1-5.
5. Crawford P, Feely M, Guberman A, Kramer G. (2006) Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15:165-176.
6. Feely M, Crawford P, Kramer G, Guberman A. (2005) Risk management in epilepsy: generic substitution and continuity of supply. The European Journal of Hospital Pharmacy Science 11:83-87.
7. Gilman JT, Alvarez LA, Duchowny M. (1993) Carbamazepine toxicity resulting from generic substitution. Neurology 43:2696-2697.
8. Guberman A, Corman C. (200) Generic substitution for brand name antiepileptic drugs: a survey. The Canadian Journal of Neurological Sciences 27:37-43.
9. Jain KK. (1993) Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example. Journal of the Royal Society of Medicine 86:133-136.
10. Jobst BC, Holmes GL. (2004) Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs 18:617-628.
11. MacDonald JT. (1987) Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 37:1885.
12. Sander JW. (2004) The use of antiepileptic drugs: principles and practice. Epilepsia 45(suppl 6):28-34.
13. Tyrer JH, Eadie MJ, Sutherland JM, Hooper WD. (1970) Outbreak of anticonvulsant intoxication in an Australian city. British Medical Journal 4:271-273.
14. Welty TE, Pickering PR, Hale BC, Arazi R. (1992) Loss of seizure control associated with generic substitution of carbamazepine. Annals of Pharmacotherapeutics 26:775-777.
15. Wilner AN. (2004) Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy & Behavior 5:995-998.
16. Wyllie E, Pippenger CE, Rothner AD. (1987) Increased seizure frequency with generic primidone. JAMA 258:1216-1217.